Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States

Thyroid eye disease (TED) is an autoimmune disease that causes inflammation and expansion of the muscles and fat in the orbit. These structural changes result in pain, ocular dysmotility, blurred vision, and appearance changes that result in a low quality of life (QOL). Acute, active disease generally presents with ocular redness, conjunctival swelling, eyelid redness and swelling, and/or pain behind or around the eyes. Retro-orbital fat tissue and extraocular muscles can enlarge markedly, leading to proptosis, diplopia, and/or compressive optic neuropathy which may compromise vision. Eyelid retraction can result in an incomplete blink and/or alterations in the tear film, causing tearing, irritation, and blurred vision. Even though TED signs and symptoms can improve as inflammation subsides, many persist over the long term [1] and continue to negatively impact QOL. More specifically, patients’ ability to work [2, 3], perform everyday tasks [4, 5], and maintain social relationships [5, 6] have been shown to chronically suffer, along with mental health [5, 7, 8]. Many patients only have one initial inflammatory episode, but an estimated 16% have an inflammatory flare after at least 6 months of stability [9], and 5% have a flare after at least 5 years of stability [10].

A recent study examined QOL in active, moderate-to-severe TED patients in the United States (US), showing a large QOL impact and mental health burden [11]. One older study in the US (n = 120) showed that TED patients continued to suffer from ocular discomfort and appearance dissatisfaction years after their initial TED diagnosis (mean follow-up time: 9.8 years) [12]. Additionally, Dutch TED patients (n = 154) who had been treated with radiotherapy or prednisone treatment continued to suffer over the long term (median follow-up time: 11.7 years) from proptosis (60%), diplopia (51%), and impaired visual acuity (worse than 20/25, 28%) [5]. As a result, both physical and mental function were markedly impaired [5]. Further, QOL was previously evaluated in two placebo-controlled trials in 171 randomized moderate-to-severe active TED patients with recent (≤ 9 months) symptom onset. Baseline QOL was measured in these patients with a TED-specific instrument (Graves’ Ophthalmopathy Quality of Life questionnaire [GO-QOL]) and demonstrated a low mean QOL score (61 out of 100) [13]. However, the long-term QOL impact of chronic TED on US patients has not been well reported. Additionally, information regarding which TED signs and symptoms persist over the long term and how these impact patient QOL is sparse. Given the ongoing development of new therapies for all phases of TED, a better understanding of chronic TED and how it impacts patient QOL is of the utmost importance. The current survey aimed to better understand the US TED population, particularly chronic TED sign and symptom persistence that interfered with tasks of daily life and impacted overall patient QOL. Potential factors that influenced QOL were also investigated.

We analyzed existing, de-identified patient survey data. Therefore, this study was assigned exempt status by the Western Institutional Review Board (IRB; Puyallup, WA). All study conduct adhered to the tenets of the Declaration of Helsinki. Patients who completed the survey were paid $85 as reimbursement for their time.

One hundred patients with inactive/chronic TED completed an online survey in January 2020. Patients with all levels of TED severity were included. A third party (Instar, New York, NY) designed the survey in collaboration with the sponsor (Horizon Therapeutics, Deerfield, IL), administered the survey, and collated data in a de-identified manner before providing it to the authors for analysis. After confirming they had a formal diagnosis of “thyroid eye disease (TED) also called Graves ophthalmopathy, thyroid-associated ophthalmopathy, and Graves orbitopathy,” patients were asked, “Is your thyroid eye disease (TED) currently active or inactive?” Patients were provided brief descriptions of both active and inactive TED for reference (Supplemental Table 1). Participants were also asked, “What phrase did the healthcare professional use when they told you that your thyroid eye disease (TED) was inactive?” The following key words/phrases were looked for as confirmation of TED inactivity: quiet, stable, inactive/no longer active, improving/overall better, dormant, less irritated/inflamed, not a lot of redness, and no longer changing.

The survey included items pertaining to demographic information, smoking status, comorbidities, age at TED diagnosis and at time of survey, TED treatment history, and thyroid levels (high, normal, or low). Treatment history items included both medical (i.e., over-the-counter pain relievers [acetaminophen, NSAIDs], glucocorticoids [topical, oral, intravenous], and biologics [rituximab, tocilizumab]) and surgical/procedural (i.e., orbital decompression, strabismus, eyelid, cosmetic, orbital radiation) treatments. Patient characteristics and TED parameters were inquired about both at the time of diagnosis and after patients were told their TED had become inactive (applicable survey items listed in Supplemental Table 2). QOL in patients with chronic TED was measured using the English version [14] of the Graves’ Ophthalmopathy Quality of Life (GO-QOL) instrument [15]. GO-QOL scores range from 0 (worst) to 100 (best), with a score of 90–100 considered normal. Overall QOL scores, along with appearance-related and visual function QOL sub-scores, were examined. Factors that potentially influenced QOL were examined by stratifying patients by overall GO-QOL score into the following terciles: low QOL (less than or equal to 50), middle QOL (between 50 and 75), and high QOL (greater than or equal to 75).

Algorithms were used to verify that data were from actual patients, identify verbatim responses, and monitor survey completion time for responses that were too rapid to be accurate or real. Incomplete surveys and those suspected of containing low-quality or imposter responses were excluded from analyses. Data are presented as mean ± standard deviation or n (%) as appropriate. Differences between groups were examined using unpaired, two-tailed Student’s t-tests for continuous parameters and two-tailed Fisher’s exact tests for categorical parameters. Statistical significance was defined as p < 0.05.

A total of 4950 patients in an existing research database were emailed an invitation to complete the survey. All patients had been profiled as having a thyroid condition, Graves’ disease, or TED to maximize the chances of reaching a TED patient (1497 [30%] previously reported TED or Graves’ disease, 3453 [70%] previously reported a thyroid condition). Of these, 773 (16%) clicked on the survey link to indicate their interest, with 206 inactive TED patients (27%) ultimately identified (567 patients did not have inactive TED). Of these 206 inactive TED patients, 100 were included in this analysis (67 did not complete the survey, 39 surveys removed for quality issues). Participants were geographically well distributed across the United States, with 35 states represented (Supplemental Figure).

This study demonstrates that TED patients in the United States continue to be negatively impacted by their disease years after TED-related inflammation has quiesced. Average TED duration at the time of survey was approximately 6 years, with 3 years of disease inactivity. The most common TED symptom reported during chronic TED was ocular dryness/grittiness, which was not surprising given the direct relationship between TED and dry eye disease [17]. Further, patients with TED have tear film aqueous deficiencies more often than patients with dry eye disease, thought to result from immune-mediated lacrimal gland dysfunction [17, 18]. QOL remained heavily impaired, as indicated by overall, vision-related, and appearance-related GO-QOL scores that averaged approximately 60 points. Interestingly, these scores were nearly identical to those observed in the teprotumumab clinical trial population of recent-onset (≤ 9 months), active, moderate-to-severe TED patients [13]. Our findings are in agreement with patient experiences [19] and prior studies outside of the US, which have shown a marked impact of TED on patient-reported QOL [20‐24]. One study of a US population of moderate-to-severe TED patients also demonstrated a decrease in QOL, as reported by physicians [11]. The current study identified several factors that influenced QOL, including the total number of reported TED signs and symptoms. More specifically, pain behind the eyes, blurry vision, light sensitivity, and diplopia were all significantly more prevalent in patients with the lowest QOL. These findings are in agreement with prior studies, which have shown relationships between QOL and TED-related pain [11, 24, 25], vision loss [11], and diplopia [11, 25‐29]. The current study also showed that patients who had undergone a surgical procedure for TED had a significantly lower QOL than patients who had not. This finding is in agreement with Terwee et al. [30], who found low mean appearance and visual function GO-QOL scores in chronic TED patients following TED-specific surgical procedures.

The heavy psychosocial health burden of TED has been previously documented in populations around the globe [8, 11, 20, 21, 25, 26, 31‐33]. In agreement, mental health issues were highly prevalent (42%) in this cohort of chronic TED patients. This rate was similar to a population of active, moderate-to-severe TED patients (36%) [11] and was more than twice as frequent as that reported in the general US adult population (“any mental illness” prevalence: 20.6% [16]). The individual prevalence of anxiety and depression was 34% and 28%, respectively, nearly identical to a small population of TED patients presenting for orbital decompression surgery (37% and 26%, respectively [8]). The proportion of patients reporting anxiety increased as QOL decreased (from 17% in the high QOL group to 48% in the low QOL group), but rates of depression were not significantly different across QOL groups.

The chronic TED patients included in this study sought medical care for TED approximately 20 times in the year prior to survey. This number increased markedly from approximately 5 TED-related doctor visits/year/patient in the high QOL group to 40 TED-related doctor visits/year/patient in the low QOL group. It is likely that the low QOL group had the highest number of severe TED cases. Prior studies have shown that QOL decreases as TED severity increases [11, 22, 26, 27, 34, 35], and it would be expected that patients with more severe TED would either seek out care more often or be followed more closely by their healthcare provider. However, because our data were patient-reported, the clinical severity of TED could not be assessed. A previous report showed that TED patients often have negative interactions with healthcare providers [21] and that quality of care impacts patient QOL [36]. In that study, only one in four patients felt they had been adequately helped to manage the psychological burdens of TED [36]. Further, physician and patient assessments of TED impact often do not align, with physicians tending to underestimate both TED-associated facial changes [37] and QOL impact of medical conditions [38, 39]. All of these factors may have contributed to the increased healthcare utilization by chronic TED patients in the low QOL group.

Compared to patients who had not received systemic glucocorticoids during active, progressive TED, QOL was the same in patients who had been treated with oral glucocorticoids and significantly higher than in patients who received IV glucocorticoids. However, in the United States, glucocorticoids, particularly IV glucocorticoids, tend to be reserved for the most severe TED patients and those with the most heavily impacted QOL [40]. Therefore, it is likely that QOL was lower in systemic GC-treated patients during acute TED. We also found that the number of surgeries increased as patient QOL decreased. Again, surgery is reserved for patients with more severe TED, and patients undergoing multiple surgeries likely had more severely impacted QOL during acute TED. It should be noted that this survey was completed prior to the commercial availability of teprotumumab, and highlights the extreme unmet need at the time for effective, disease-modifying treatments for TED.

This study had several limitations. First, our sample size was relatively small. Second, TED phasing and clinical information relied upon patient knowledge of their condition in both the present and the past. Of the 206 patients initially identified as having inactive TED, only 100 were included in analyses. This may have biased our results towards patients who were the least satisfied, because unsatisfied patients tend to be more vocal than satisfied ones. We are confident that patients in this survey had inactive TED, as the vast majority (75%) of patients reported their physician using at least one confirmatory word/phrase for inactive TED, with 49% specifically reporting the words “inactive” or “no longer active.” However, for patient-reported outcome measures, the Food and Drug Administration (FDA) recommends a short recall period because a patient’s current state can influence how they report a past state [41]. Because the survey asked patients to recall information from several years prior, it is possible that recall errors and biases were introduced. That said, the survey results correspond well with what is seen in clinical practice. TED patients with moderate-to-severe disease are often very discontent despite therapeutic interventions, have persistent mental health challenges, and have interpersonal issues that make social and professional relationships difficult. Lastly, our study population was approximately half male, which could be viewed as unexpected given the higher proportion of women reported in the overall TED population [11, 42]. However, this higher female proportion might not be found in more symptomatic chronic, inactive patients, as this has not yet been evaluated in large epidemiological studies. Male and female patients in our study had similar demographics, TED symptom reporting, and overall GO-QOL scores. Therefore, it is unlikely that the high proportion of males influenced study findings for this chronic TED population.

Patient QOL is markedly impacted by TED on a chronic basis, and the QOL scores reported here are very similar to those reported in more active patients. Both patient appearance and visual function remain affected over the long term in many TED patients due to the persistence of TED signs and symptoms into the chronic presentation of the disease. As potential treatments for chronic TED emerge [43, 44], having a better understanding of clinical presentation and impact of QOL becomes increasingly important. Further exploration is warranted to better understand the impact of chronic TED on QOL, particularly with prospective, longitudinal studies that include both patient-reported outcomes and clinical examination.